Bladder cancer – RCR consensus statements
Date: 2023
Date of next review: 2027
|
Please note: Radiotherapy Dose Fractionation Third Edition and Timely Delivery of Radical Radiotherapy: guidelines for the management of unscheduled treatment interruptions, fourth edition are both currently under review and due to be published later in 2023. You should therefore refer to the Bladder Consensus Statements for the latest guidance on radical and palliative fractionation schedules for bladder cancer, and how treatment interruptions should be managed in the bladder cancer patient (i.e. bladder cancer should be treated as a Category 1 tumour). |
The RCR consensus process was initially developed in 2016 to help reduce variation in UK radiotherapy practice. The bladder cancer consensus statements should serve as a practical stimulus for bladder cancer teams to review their current radiotherapy service to ensure that they are able to deliver optimal treatment for their patients. They should be adopted in parallel with relevant National Institute for Health and Care Excellence (NICE) guidance.
These areas are covered by the consensus statements in this document:
- Pathway and Follow up
- Systemic Anti-Cancer Treatment
- Technical Aspects of Radiotherapy – radical, high dose palliative and palliative
- Node Positive Disease
- Variant Pathology
